Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinical trial of
View HTML
Toggle Summary Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
New Analyses Demonstrate Statistical Non-Inferiority of 0.5% Reproxalap Ophthalmic Solution to Corticosteroid
View HTML
Toggle Summary Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results
LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference
LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results
LEXINGTON, Mass. , Nov. 2, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will issue
View HTML
Toggle Summary Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
LEXINGTON, Mass. , Oct. 25, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present
View HTML
Toggle Summary Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting
ADX-102 Reduces Toxic Levels of Gamma-Hydroxybutyrate and Gamma-Aminobutyrate in Brain Tissue from Knockout Mouse Model
View HTML
Toggle Summary Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day
Dry Eye Disease Clinical Activity Correlated with Aldehyde ReductionEfficacy of ADX-102 in Allergic Conjunctivitis Demonstrated to be Clinically RelevantADX-103, a New Aldehyde Trap, Active in Three Preclinical Models of Retinal Disease
View HTML
Toggle Summary Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting
Abstract Designated Reviewers' Choice Abstract, Representing Top 10% of Submissions
View HTML
Toggle Summary Aldeyra Therapeutics Announces 2017 Research and Development Day
LEXINGTON, Mass. , Sept. 27, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity today announced that it will host
View HTML